PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V1044 - Common Stock
CATX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. While CATX seems to be doing ok healthwise, there are quite some concerns on its profitability. CATX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CATX had negative earnings in the past year.
CATX had a negative operating cash flow in the past year.
In the past 5 years CATX always reported negative net income.
In the past 5 years CATX always reported negative operating cash flow.
1.2 Ratios
CATX's Return On Assets of -22.72% is fine compared to the rest of the industry. CATX outperforms 78.63% of its industry peers.
The Return On Equity of CATX (-25.42%) is better than 83.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -25.42% | ||
| ROIC | N/A |
ROA(3y)-18.62%
ROA(5y)-40.12%
ROE(3y)-25.79%
ROE(5y)-55.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of CATX (22.97%) is better than 75.73% of its industry peers.
CATX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CATX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.84%
GM growth 5Y19.37%
2. Health
2.1 Basic Checks
CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has more shares outstanding
The number of shares outstanding for CATX has been increased compared to 5 years ago.
The debt/assets ratio for CATX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 43.40 indicates that CATX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 43.40, CATX belongs to the best of the industry, outperforming 96.24% of the companies in the same industry.
CATX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CATX has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 43.4 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
CATX has a Current Ratio of 2.67. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CATX (2.67) is worse than 69.91% of its industry peers.
CATX has a Quick Ratio of 2.55. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.55, CATX is not doing good in the industry: 69.40% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.55 |
3. Growth
3.1 Past
CATX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
CATX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.46%.
The Revenue has been growing by 17.80% on average over the past years. This is quite good.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y17.8%
Revenue growth Q2Q-83.98%
3.2 Future
The Earnings Per Share is expected to decrease by -16.40% on average over the next years. This is quite bad
CATX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.86% yearly.
EPS Next Y-171.99%
EPS Next 2Y-35.5%
EPS Next 3Y-17.74%
EPS Next 5Y-16.4%
Revenue Next Year-25.94%
Revenue Next 2Y-78.81%
Revenue Next 3Y-27%
Revenue Next 5Y4.86%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CATX's earnings are expected to decrease with -17.74% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.5%
EPS Next 3Y-17.74%
5. Dividend
5.1 Amount
No dividends for CATX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PERSPECTIVE THERAPEUTICS INC
NYSEARCA:CATX (5/17/2024, 7:04:02 PM)
After market: 1.61 +0.01 (+0.63%)1.6
+0.07 (+4.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap939.52M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -25.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 22.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-171.99%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y